Jacobs Levy Equity Management, Inc Arvinas, Inc. Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $1.32 Million - $1.9 Million	-36,311 Reduced 77.65%	10,450 $431,000
Q4 2023 Feb 14, 2024	SELL	$14.19 - $42.33 $1.04 Million - $3.11 Million	-73,354 Reduced 61.07%	46,761 $1.92 Million
Q3 2023 Nov 16, 2023	BUY	$19.64 - $28.21 $574,273 - $824,860	29,240 Added 32.18%	120,115 $2.36 Million
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $1.97 Million - $2.86 Million	90,875 New	90,875 $2.26 Million
Q4 2019 Feb 14, 2020	SELL	$15.39 - $44.38 $204,687 - $590,254	-13,300 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$21.55 - $27.61 $286,615 - $367,213	13,300 New	13,300 $287,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.